Javier Ampuero, Ana Lucena, Marina Berenguer, Manuel Hernández-Guerra, Esther Molina, Judith Gómez-Camarero, Carlos Valdivia, Elena Gómez, Marta Casado, Carmen Álvarez-Navascuez, Francisco Jorquera, Luisa García-Buey, Álvaro Díaz-González, Rosa Morillas, Montserrat García-Retortillo, Jose Manuel Sousa, Indhira Pérez-Medrano, Miguel Ángel Simón, Javier Martínez, Juan Arenas, María Carlota Londoño, Antonio Olveira, Conrado Fernández-Rodríguez
BACKGROUND AIMS: The landscape in primary biliary cholangitis (PBC) has changed with the advent of second-line treatments. However, the use of obeticholic acid (OCA) and fibrates in PBC-related cirrhosis is challenging. We assessed the impact of receiving a second-line therapy as a risk factor for decompensated cirrhosis in a real-world cirrhotic PBC population, and identify the predictive factors for decompensated cirrhosis in these patients. APPROACH RESULTS: Multicenter study enrolling 388 PBC-cirrhotic patients from the Spanish ColHai registry...
March 6, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases